These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 27423962)

  • 21. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's Disease Composite Score: A Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease.
    Hendrix SB; Soininen H; van Hees AMJ; Ellison N; Visser PJ; Solomon A; Attali A; Blennow K; Kivipelto M; Hartmann T
    J Prev Alzheimers Dis; 2019; 6(4):232-236. PubMed ID: 31686094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Usefulness of the 10 pictures reminding test for memory assessment for the diagnosis of Alzheimer's disease, mild cognitive impairment and anxiety/depression].
    Federico D; Thomas-Anterion C; Borg C; Foyatier Michel N; Dirson S; Laurent B
    Rev Med Interne; 2008 Oct; 29(10):766-72. PubMed ID: 18692277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project.
    Ritchie K; Ropacki M; Albala B; Harrison J; Kaye J; Kramer J; Randolph C; Ritchie CW
    Alzheimers Dement; 2017 Feb; 13(2):186-195. PubMed ID: 27702619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Outcome and cognitive changes of mild cognitive impairment in the elderly: a follow-up study of 47 cases].
    Xiao SF; Xue HB; Li GJ; Li CB; Wu WY; Zhang MY
    Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(21):1441-6. PubMed ID: 16842692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
    Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
    Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
    JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
    Dichgans M; Markus HS; Salloway S; Verkkoniemi A; Moline M; Wang Q; Posner H; Chabriat HS
    Lancet Neurol; 2008 Apr; 7(4):310-8. PubMed ID: 18296124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Education and rates of cognitive decline in incident Alzheimer's disease.
    Scarmeas N; Albert SM; Manly JJ; Stern Y
    J Neurol Neurosurg Psychiatry; 2006 Mar; 77(3):308-16. PubMed ID: 16484637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.
    Devanand DP; Pelton GH; Zamora D; Liu X; Tabert MH; Goodkind M; Scarmeas N; Braun I; Stern Y; Mayeux R
    Arch Neurol; 2005 Jun; 62(6):975-80. PubMed ID: 15956169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
    Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
    Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of neuropsychological and functional outcomes in Alzheimer's disease patients with good or bad response to a cognitive stimulation treatment: a retrospective analysis.
    Martínez-Moreno M; Cerulla N; Chico G; Quintana M; Garolera M
    Int Psychogeriatr; 2016 Nov; 28(11):1821-1833. PubMed ID: 27503001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI).
    Walsh SP; Raman R; Jones KB; Aisen PS;
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S170-8. PubMed ID: 17135810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration.
    Rozzini L; Chilovi BV; Conti M; Bertoletti E; Delrio I; Trabucchi M; Padovani A
    Int J Geriatr Psychiatry; 2007 Dec; 22(12):1217-22. PubMed ID: 17562522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration.
    Burback D; Molnar FJ; St John P; Man-Son-Hing M
    Dement Geriatr Cogn Disord; 1999; 10(6):534-40. PubMed ID: 10559571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive impairment in Alzheimer's disease is modified by APOE genotype.
    van der Vlies AE; Pijnenburg YA; Koene T; Klein M; Kok A; Scheltens P; van der Flier WM
    Dement Geriatr Cogn Disord; 2007; 24(2):98-103. PubMed ID: 17596691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study.
    Burnham SC; Raghavan N; Wilson W; Baker D; Ropacki MT; Novak G; Ames D; Ellis K; Martins RN; Maruff P; Masters CL; Romano G; Rowe CC; Savage G; Macaulay SL; Narayan VA; ;
    J Alzheimers Dis; 2015; 46(4):1079-89. PubMed ID: 26402634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.